Advertisement

Topics

Alnylam suspends dosing in bleeding disorder study after patient death

09:12 EDT 7 Sep 2017 | Reuters

(Reuters) - Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies after one patient died.

Original Article: Alnylam suspends dosing in bleeding disorder study after patient death

NEXT ARTICLE

More From BioPortfolio on "Alnylam suspends dosing in bleeding disorder study after patient death"

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...